tp-1287
Dedifferentiated Liposarcoma
Sumitomo Pharma America, Inc.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Dedifferentiated Liposarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Stc-15 STORM Therapeutics LTD | Phase 1/2 | CC |
Toripalimab STORM Therapeutics LTD | Phase 1/2 | CC |
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- STORM Therapeutics LTD | Phase 1/2 | CC |
okn4395 Epkin | Phase 1 | CC |
Pembrolizumab Epkin | Phase 1 | CC |
Same molecule, other indications
tp-1287 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →